Overview

Neoadjuvant INBRX-106 (Hexavalent OX40 Agonist) in Combination With Pembrolizumab as a Chemotherapy-sparing Regimen for Stage II TNBC (Triple Negative Breast Cancer) Patients

Status:
RECRUITING

Trial end date:
2029-06-01

Target enrollment:

Participant gender:

Summary

This is a Phase II trial to assess feasibility of pembrolizumab + INBRX-106 as a chemotherapy-sparing neoadjuvant therapy. One therapeutic arm is being evaluated to provide an informal comparison of pharmacodynamic and clinical effects of concurrent dosing schedule.

Phase:

PHASE2

Details

Lead Sponsor:

Providence Health & Services

Collaborator:

Inhibrx Biosciences, Inc

Treatments:

pembrolizumab